Share on StockTwits

Leerink Swann dropped their price target on shares of Kindred Biosciences (NYSE:KIN) from $29.00 to $11.25 in a research note issued on Thursday. Leerink Swann’s price objective would indicate a potential downside of 23.00% from the company’s current price.

KIN has been the subject of a number of other recent research reports. Analysts at Roth Capital cut their price target on shares of Kindred Biosciences to $11.50 in a research note on Thursday. Analysts at Craig Hallum initiated coverage on shares of Kindred Biosciences in a research note on Friday, May 23rd. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $17.58.

Kindred Biosciences (NYSE:KIN) opened at 14.21 on Thursday. Kindred Biosciences has a one year low of $8.75 and a one year high of $26.99. The stock’s 50-day moving average is $15.89 and its 200-day moving average is $18.09. The company’s market cap is $280.1 million.

Kindred Biosciences (NYSE:KIN) last announced its earnings results on Wednesday, August 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.07. On average, analysts predict that Kindred Biosciences will post $-1.75 earnings per share for the current fiscal year.

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.